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ZIKA VIRUS: CONTROL MEASURES FOR AN EMERGING PATHOGEN IN 
BRAZIL  
ALYSSA STETSON 
ABSTRACT 
 
 Zika virus (ZIKV), a member of the flavivirus family, was discovered in 
the Zika Forest of Uganda in 1947, subsequently diverged into two strains, and 
spread throughout Africa and Asia. Although it is believed to be endemic in 
these regions, its overall effects have been considered relatively benign, 
especially in comparison to other flaviviruses like dengue virus (DENV) and 
yellow fever virus (YFV). ZIKV is believed to have reached Brazil between June 
and August of 2014, although it may have arrived as early as between May and 
December 2013; by November 2014 doctors were reporting an increased 
incidence of cases with flu-like symptoms, and by March 2015 an increased 
incidence of microcephaly. These reports prompted an investigation into a 
possible association between ZIKV and microcephaly. Proof of causality can be 
illustrated through Shepard’s Criteria of Teratogenity “rare exposure-rare 
defect” approach, meeting the criteria of proven exposure to the agent, careful 
delineation of clinical cases, and rare environmental exposure with rare defect. 
		 v 
Additionally, laboratory findings have discovered several possible mechanisms 
by which ZIKV can be vertically transmitted, as well as confirming that ZIKV is 
neurovirulent and disrupts the development of brain structures, especially when 
infection occurs during the first trimester. ZIKV is also possibly associated with 
other neurologic disorders: retrospective findings from a 2013 outbreak on 
French Polynesia linked ZIKV to the neurologic disorder Guillain-Barré 
syndrome (GBS).  
 Microcephaly places a significant burden, both emotional and financial, on 
the affected families and the healthcare system. Therefore, there has been 
significant effort to develop a vaccine against ZIKV. While ZIKV is a suitable 
vaccine candidate in some aspects, it also has characteristics that make vaccine 
development challenging. First, the vaccine must be safe for pregnant women, 
since protecting them from disease transmission is the primary goal. Second, the 
vaccine must not cause adverse effects through cross-reacting antibodies, which 
may lead to antibody-dependent enhancement of infection in people who have 
been vaccinated against or infected with other flaviviruses, especially DENV. 
Currently, there are multiple vaccines in the earliest stages of development with 
three vaccines in Phase 1 trial. Researchers are also testing monoclonal antibodies 
		 vi 
and antimicrobial drugs for effectiveness against ZIKV. Given the high cost of 
these treatments they should be prioritized for pregnant women.  
ZIKV can be spread through vector transmission, sexual transmission, or 
blood transfusion. Although vaccine development is the ultimate goal, the most 
effective way of curtailing ZIKV transmission and reducing incidence of 
microcephaly is through vector control. Brazil already has vector control 
strategies in place to combat other mosquito-borne diseases, especially DENV, 
but its monitoring systems do not always accurately assess mosquito population 
density and location. There is also an overreliance on insecticide use, which is 
often ineffective and leads to mosquito resistance and potentially environmental 
damage. The most effective strategy for vector control is reduction of breeding 
sites through drainage of standing water, waste management and education 
about mosquitoes and personal protection measures. 
 The other key strategy to reducing ZIKV transmission and the incidence 
of microcephaly is through education about condom use and access to safe 
abortions. While Brazil has worked to improve the former in the context of the 
HIV epidemic, with some success, abortions in Brazil are restricted. Data are 
scarce, but suggests that the number of women seeking abortions has increased 
		 vii 
due to ZIKV epidemic; limiting abortions leaves them vulnerable to unsafe 
procedures and at risk for complications that are avoidable.  
 The ultimate goal for preventing ZIKV-associated congenital 
microcephaly, and other negative consequences of infection, is the development 
of a vaccine. However, implementing prevention methods against all 
mechanisms of ZIKV transmission is the best option to reduce the public health 
burden until such goal is achieved.   
		 viii 
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INTRODUCTION 
 
 On February 1, 2016, the World Health Organization (WHO) established 
the vector-borne flavivirus Zika virus (ZIKV) to be a Public Health Emergency of 
International Concern in response to the outbreak in Brazil over the previous 
year and a half (1). Although the symptoms of ZIKV are rarely severe, doctors 
had been reporting an 
increased incidence of 
microcephaly and 
retrospective findings 
indicated that this 
virus could be linked 
to other neurological conditions. This was the first time that ZIKV has drawn 
widespread concern, although the virus has been known about for decades. It 
was discovered in 1947 when it was isolated from a rhesus macaque monkey in 
the Zika Forest of Uganda, with the first cases of human infection probably 
occurring in the 1950s in Uganda (3,4,5). ZIKV subsequently diverged into the 
African and Asian strains and spread throughout Africa, Asia, and Oceania 
(Figure 1). It is believed to be widespread throughout these parts of the world, 
Figure 1. The spread of ZIKV from Africa (2). 
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but the ability to detect ZIKV with serosurveillance is limited due to its close 
serological similarity to dengue virus (DENV) and West Nile virus (WNV) (5). 
ZIKV is transmitted through mosquitoes like other flaviviruses, but uniquely 
also can be sexually transmitted (6). 
The first large outbreak of ZIKV, identified retrospectively, occurred in 
2007 on the Micronesian island of Yap (7). Doctors noted multiple cases of an 
illness characterized by rash, conjunctivitis, subjective fever, arthralgia, and 
arthritis. The symptoms were similar to DENV, and the commercially available 
assay for IgM suggested that DENV was the causative pathogen, but the 
physicians felt that it was clinically distinct and so pursued subsequent testing. 
Final diagnosis was based on detailed serological analysis and reverse 
transcriptase polymerase chain reaction (RT-PCR) sequencing that showed a 
pathogen 90% similar to ZIKV (7). A total of 185 suspected cases of ZIKV were 
identified, of which 108 (58%) were confirmed or considered probable cases. 
DENV RNA was absent in the 137 cases with available acute-phase specimens. 
The authors of this study believe that ZIKV had not been present on Yap 
previously, due to the clustering of cases in May and June and the high 
prevalence of IgM antibodies. Interestingly, no association was reported with 
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microcephaly or other neurological diseases, even though in total approximately 
three quarters of the population of Yap was infected (8).  
No further outbreaks were reported until October 2013, in French 
Polynesia, when approximately 11% of the population sought medical care for 
suspected cases of ZIKV. The actual number of cases of ZIKV was believed to be 
higher since it was estimated that only 20% of those infected were symptomatic 
(8). Once again the majority of patients had mild symptoms: 90% presented with 
a pruritic maculopapular rash, 65% with arthritis/arthralgia, and 65% with a 
fever (1). Other common symptoms included nonpurulent conjunctivitis and 
myalgia, similar to those of other arboviruses such as chikungunya (CHIKV) and 
DENV virus (8). However, for the first time there was a spike in the incident rate 
of Guillain-Barré syndrome (GBS), an autoimmune disease causing acute 
ascending or subacute flaccid paralysis. At the time, there was no association 
noted between ZIKV and microcephaly (9).  
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After the 2013 French Polynesian outbreak, cases were reported in New 
Caledonia, Easter Island, and the Cook Islands, but there were no major 
outbreaks until the virus reached Brazil. 
As early as August of 2014 doctors began 
to identify multiple cases of a DENV-like 
virus, and so in March of 2015 tested the 
serum samples of 24 patients from a 
hospital in Camaçari, Bahia (outside of Salvador) for DENV, CHIKV, WNV, 
Mayaro virus, and ZIKV using RT-PCR. No patients tested positive for DENV, 
WNV, or Mayaro virus; 7 patients (29.5%) were positive for ZIKV and 3 (12.9%) 
were positive for CHIKV (10). Also in March 2015, sampling was done on 
patients from Natal, Rio Grande do Norte with results indicating the presence of 
ZIKV.  Samples from patients from both outbreak locations showed high 
homology to the ZIKV virus from French Polynesia. However, given that 
Camaçari and Natal are 1000km apart (Figure 2), ZIKV likely arrived in Brazil at 
separate introduction sites. Theories for the event of introduction include the 
Confederations Cup Soccer tournament in June 2013, the World Cup in June-July 
of 2014, or the IVF Va'a World Elite and Club Sprint Championship (an outrigger 
canoe race) held in August, 2014 (7,11).  
Figure 2. Introduction of ZIKV to Brazil (7) 
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ZIKV, although prevalent in Africa, had not previously been associated 
with microcephaly. However, in October of 2015 doctors in Brazil began noticing 
an unusually high number of babies born with microcephaly and by November 
of 2015, WHO had received reports of 739 cases of microcephaly in nine states of 
northeastern Brazil: the same region as the ZIKV outbreak (12). This was 
markedly higher than the nationwide incidence before the ZIKV outbreak, which 
was below 200 per year (13). The higher than normal incidence of microcephaly, 
coupled with the ZIKV outbreak, prompted investigation into a possible link 
between ZIKV and microcephaly. Since then, studies have shown that ZIKV can 
cause microcephaly in mice, and ZIKV infection during pregnancy is now 
associated with, and likely causative for, severe fetal abnormalities including 
microcephaly/micrencephaly, lissencephaly, hydrocephaly, necrosis, 
periventricular and cortical calcifications, diffuse astrogliosis, hypoplasia of the 
brain stem and spinal cord, Wallerian degeneration of the corticospinal tract, and 
ocular abnormalities (14).  
 ZIKV is an example of an emerging disease that has rapidly become 
widespread (Figure 3) and that has the potential to inflict far more damage than 
previously believed, due to its association with microcephaly and possible link 
with other neurologic diseases. This review focuses on what is known about the 
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viral mechanism and the evidence of causality of microcephaly, and then 
discusses possible interventions that can decrease the number of those affected 
with microcephaly in Brazil.  
 
Figure 3.  Map of countries affected by ZIKV as of January 17, 2017 (15). 
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Viral Mechanism 
Structure 
 ZIKV has an icosahedral 
outer envelope and dense inner 
core containing one positive 
single strand RNA genome 10.7 
kb in length (4). The genome 
codes for 10 total proteins: 3 
structural and 7 non-structural. 
The three structural proteins are the capsid protein (C), the premembrane protein 
(prM) and the envelope protein (E). The 7 non-structural proteins (NS1, NS2A, 
NS2B, NS3, NS4A, NS4B, and NS5) contribute to virus replication and immune 
evasion. It has 2 untranslated regions, one of 107 nucleotides and the other of 429 
nucleotides. The 5’ end has a type 1 cap structure while the 3’ end has a 
polyadenylate tail with conserved structures (Figure 4)(4). The N-terminus 
contains the methyltransferase and guanyltransferase activities that contribute to 
the formation of the 5’ cap while the C-terminus contains the RNA-dependent 
RNA polymerase (RdRp) that facilitates synthesis of new viral genomes (17).   
Figure 4. Structure of ZIKV (16). 
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 Overall the structure of ZIKV envelope protein is similar to that of DENV 
envelope protein, except for the glycosylation sites: the ZIKV mature virion has 
an insertion within the glycosylated loop of E while the DENV virion does not 
(18). This difference might impact the transmission and neurovirulence of ZIKV 
since a comparison between WNV strains showed that those with the same 
insertion as ZIKV were more virulent than those without the insertion (6,19). The 
African and Asian strains vary by 3-5% at the amino acid level (17). 
Replication  
 The replication of ZIKV is similar to other flaviviruses and occurs in the 
endoplasmic reticulum (ER), although ZIKV antigens have only been found in 
the nuclei of infected cells, suggesting that perhaps it has a different method of 
replication (5). If similar to other flaviviruses, the virus enters the cell via 
endocytosis with an unknown receptor, most likely clathrin dependent (20), or 
facilitated by the AXL receptor tyrosine kinase factor (5). After fusion occurs the 
genome is released and translated in the ER as a single polyprotein, which is then 
processed by NS2B-NS3 protease and other cellular proteases to generate mature 
viral proteins. Subsequently, the positive viral RNA genome is copied to 
negative sense, which serves as a template for the full-length positive-sense 
genomic RNA. Synthesis happens in the ER, then the new genomes are packaged 
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by the C protein and acquire the envelope while budding from the ER, to form 
immature virions. Immature virions have spiky surfaces with 180 copies each of 
E and prM protein and are transformed via E glycosylation and cleavage of prM 
by host furin protease to form mature virions, which have a smooth surface with 
antiparallel E protein heterodimers and cleaved M proteins lying on the envelope 
(6).  
Transmission 
Vector 
 The most common route of infection is through mosquito bites, primarily 
by the Aedes mosquito. The Ae. aegypti species appears to be the major vector in 
Asia, was most likely the primary vector in the French Polynesian outbreak, and 
was responsible for the spread of ZIKV in Brazil. In Africa, the Ae. albopticus is 
hypothesized to be the primary vector and was likely responsible for a ZIKV 
outbreak in Gabon in 2007. Ae. albopticus is also widespread in the U.S. and so 
could potentially serve as the primary vector if an outbreak were to occur in 
North America, although thus far the Ae. Aegypti has been the only vector. As 
with other vector-borne diseases, human transmission is difficult to curtail since 
the virus survives in non-human reservoirs. ZIKV most likely has multiple non-
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human reservoirs since antibodies or the virus itself have been isolated from 
various nonhuman primates as well as from other wild and domestic animals (5). 
Once the mosquito has broken the skin, primary dermal fibroblasts, 
epidermal keratinocytes, and immature dendritic cells are permissive for the 
ZIKV infection. Cellular autophagy, needed for flavivirus replication, enhances 
ZIKV replication in skin fibroblasts (5). The virus then spreads to the lymph 
nodes where it is amplified, and is carried by the blood to peripheral tissues and 
visceral organs (4). 
Sexual 
 The first report of possible sexual transmission of ZIKV was in 2008 when 
an American scientist working in Senegal, upon return to the U.S., infected his 
wife via sexual intercourse (21). The possibility for sexual transmission was 
confirmed when ZIKV was isolated from the semen of a man in Tahiti during the 
2013 French Polynesian outbreak. This also served as confirmation that sexual 
transmission was possible from an asymptomatic patient since the virus was 
present in the semen at least 14 days after diagnosis (9).  
Although originally believed to only be transmitted through semen, in 
July 2016 the first case of female-to-male sexual transmission in was reported 
New York City (22). As of January 18, 2017, there have been 38 cases of sexual 
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transmission within the U.S. The majority of these have been symptomatic male-
to-female, but there have also 
been instances of asymptomatic 
male-to-female, symptomatic 
female-to-male, and 
asymptomatic female-to-male 
(23). Worldwide sexual 
transmission of ZIKV was 
reported in eleven countries (U.S., 
Italy, France, Germany, New Zealand, Argentina, Chile, Peru, Portugal, and 
Spain) as of August 2016 (24). 
 During the initial weeks post-infection, the virus is excreted in relatively 
high loads from the urine, saliva, and other bodily fluids. While viral shedding 
from the urine and saliva has been reported for other flaviviruses, ZIKV is 
unique in its tropism for testicular tissue and for being shed in the semen (6). 
Vertical 
 Most worrying in the case of the current ZIKV outbreak is the possibility 
for placental infection. Studies have confirmed transmission through the 
following findings: ZIKV RNA in the amniotic fluid and fetal and newborn brain 
Short Article
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Figure 5. Maternal-Fetal ZIKV Transmission (25) 
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tissue; ZIKV-specific IgM in the newborn cerebrospinal fluid; ZIKV antigens in 
the chronic villi of a mother who gave birth to a child with microcephaly; ZIKV 
antigen in the placental tissue of mice infected with ZIKV; and ZIKV antigen in 
the placenta of a mother diagnosed with ZIKV.  ZIKV antigens have specifically 
been detected from placental macrophages and histiocytes in the intervillous 
space, implicating these cells in the mechanism of transmission. Identifying this 
mechanism is key to discovering an antiviral therapy that could effectively target 
the maternal cells permissive to ZIKV replication, thereby preventing 
transmission to the fetus (25). 
Quicke et al. demonstrated that syncytiotrophoblasts (differentiated 
cytotrophoblasts [CTBs]) and placental macrophages (Hofbauer cells [HC]) are 
both permissive to infection by a ZIKV strain similar to the one currently 
circulating in Brazil, although CTBs to a lesser extent. HCs respond to infection 
by triggering antiviral defense programs, IFN-𝛼 and other pro-inflammatory 
cytokines, rather than dying. Analysis of antiviral gene expression also shows 
upregulation of retinoic acid-inducible gene I-like receptor transcription as well 
as downstream antiviral effector genes, confirming that ZIKV produces an 
antiviral response in HCs and CTBs (Figure 5) (25). 
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In addition to showing that HCs and CTBs are permissive to ZIKV 
infection, Quicke et al. also found variation in viral kinetics and magnitude of 
response to ZIKV infection that was not necessarily proportionate to the amount 
of viral RNA present. It was hypothesized that this difference could be due to the 
different rates of genome replication, so that donors with the same amount of 
viral RNA present at the initial time of infection had different amounts of viral 
RNA present at 24 hours post-infection. These findings suggest that maternal 
genetics may cause variation in the ability to restrict ZIKV replication at different 
points in its life cycle. This might also relate to observed differences in 
intrauterine transmission efficiency, so that mothers with HCs that are more 
susceptible to infection might support a higher rate of viral replication, and thus 
have a higher likelihood of transmitting the infection to the fetus (25).  
These same authors speculate that one possible mechanism of 
transmission across the placenta to infect HCs is through initial infection of 
trophoblasts. These cells allow for ZIKV replication and dissemination of the 
virus into HCs, which subsequently efficiently support ZIKV replication. An 
alternative explanation is that non-neutralizing, cross-reactive antibodies bind 
ZIKV and traffic across the placenta, subsequently infecting placental 
macrophages. Regardless of the route, there is then dissemination throughout the 
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cord blood and infection of neural progenitor cells (24). Once infected, human 
cortical neural progenitor cells (hNPCs) release infectious ZIKV particles (4). 
 A different study by Zhang et al. focused more on the involvement of 
CTBs than HCs in placental infection due to finding that ZIKV was detected in 
the chorionic villi and not the maternal decidua (4).  Two possible routes for 
vertical transmission were suggested, based on the two zones of contact between 
the uterus and the placenta. The first zone of contact is the basal decidua which 
develops from placental CTBs. As above, the researchers commented on the 
variation in ability of ZIKV to infect CTBs: they found that ZIKV could not infect 
them after late gestation due to the secretion of type III interferon. However, 
ZIKV infection with both NS3 and E expression in foci of proliferating CTBs near 
the villus core and invasive CTBs expressing HLA-G were identified. Thus, there 
is a potential role for antibody-mediated transcytosis of IgG-ZIKV by neonatal Fc 
receptor expressed in syncytotrophoblasts and infection of underlying CTBs. 
This could cause enhanced infectivity of HCs. The second zone of contact is the 
parietal decidua, which has both a larger surface area and remains in contact 
from mid-gestation through delivery. It is thought that ZIKV could disseminate 
from uterine blood vessels to invasive CTBs to fetal membranes, from which 
	 15	
virions would be released into amniotic fluid and infect permissive dermal cells 
(26).  
Diagnosis  
 The difficulty in diagnosing ZIKV contributed to the challenge of 
curtailing the most recent outbreak. Currently, according to European Centre for 
Disease Control and Prevention, a case is confirmed if one of the following 
criteria are met: detection of ZIKV RNA or antigens in a clinical specimen; viral 
isolation from a clinical specimen; detection of ZIKV specific IgM antibodies in 
serum samples and confirmation by neutralization test; or seroconversion or 
four-fold increase in the titer of ZIKV-specific antibodies in paired sample 
serums. A case is considered probable if ZIKV-specific IgM antibodies are 
detected in serum but further confirmatory tests are not performed (27).  
One problem with testing for ZIKV is that viremia occurs only in the most 
acute phase of the disease, during which time molecular amplification via RT-
PCR is the preferred testing method since the ZIKV IgM may be undetected by 
serological testing (5,6). After the acute phase has passed serological testing can 
be used. Specific IgM antibodies against ZIKV appear about 9.1 days after 
infection, which is about 4-7 days after the onset of symptoms. They are usually 
detectable for about 2-3 months after infection although they may persist for 
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years. IgG antibodies are normally detectable for months to years after infection 
and may confer lifelong immunity (6). A barrier to establishing clinical cases is 
that ZIKV IgM and IgG cross-react with other flaviviruses, particularly DENV, 
but also potentially in patients immunized with YFV or JEV, or infected with 
WNV or St. Louis encephalitis. Positive tests should be confirmed by another 
method, ideally neutralizing antibody assays (i.e. plaque reduction 
neutralization tests [PRNT]), which thus far remain the gold standard for 
diagnosis (5).  
This might be changing: recently one group developed and tested the 
Euroimmun ZIKV IgG ELISA. It is believed to be sufficiently specific to rule out 
ZIKV infection, even with pre-existing infections from other flaviviruses 
(including DENV). So far it has only been tested on German travelers returning 
from Brazil, and so future tests are needed on sera from patients who live in an 
area with endemic ZIKV (27).   
Given the high cost of testing and the limited availability of diagnostic 
tests for ZIKV, certain groups should be prioritized. These include pregnant 
women (especially when there is concern of a congenital mutation or suspicion of 
ZIKV infection), couples wishing to conceive who have visited or lived in an 
endemic area, those with GBS or other neurological symptoms, and travelers 
	 17	
returning from countries where ZIKV is endemic (as well as their sexual 
partners) for surveillance and vector purposes. However, thus far couples 
wishing to conceive and travelers returning from ZIKV-endemic areas have not 
been prioritized in the U.S. have not been prioritized for testing. 
Effects of ZIKV  
Clinical manifestations 
 Infection is asymptomatic in the majority of ZIKV cases (~80%), and when 
clinical manifestations occur, they are almost always mild, comparable to mild 
infection with the other flaviviruses (7). Symptoms typically include rash, fever, 
arthralgia, myalgia, fatigue, headache, and conjunctivitis. The rash is the most 
prominent feature; it is maculopapular and pruritic, and often begins proximally 
and spreads to the extremities before resolving within 1-4 days. Symptoms 
normally resolve within 2 weeks. Age does not seem to predict symptomatic 
infection, although data from the Yap and Puerto Rico outbreaks indicate that 
gender might play a role (5,28). During the Yap outbreak the attack rate was 
higher among females than males but the discrepancy in symptoms was 
suggested to perhaps result from care-seeking behavior since the prevalence of 
the IgM antibody among participants was higher in males 87). In Puerto Rico, 
between November 1, 2015 and October 20, 2016, the incidence of ZIKV among 
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females was greater than among males and the majority of cases occurred among 
women. Furthermore, among suspected cases of ZIKV a greater percentage of 
women tested positive than men, provoking questions as to whether the gender-
based discrepancy among cases in Yap could in fact be attributed to care-seeking 
behavior (29). Further research is needed into the gender-based discrepancies in 
ZIKV infectivity and pathogenicity.  
 ZIKV is linked to serious neurological disorders, including congenital 
microcephaly, GBS, acute meningoencephalitis, and myelitis. Nonneurological 
sequelae have also been reported, including transient hearing loss, hypotension, 
genitourinary symptoms, and hematospermia (5). There have also been rare 
reports of deaths, with nine ZIKV-linked diseases reported in Brazil in 2015 and 
2016 (30). 
Microcephaly 
 The most serious concern 
thus far arising from ZIKV is the 
threat of congenital 
microcephaly. Microcephaly is 
broadly defined as a disproportionately small head. More specifically, 
microcephaly is present if the head is at least two standard deviations below the 
Figure 6. Microcephaly (31). 
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mean, which has been the definition used by Brazil in reporting cases (Figure 6). 
A more stringent definition is a head circumference three standard deviations 
below the mean, and so Brazil’s use of the former has led to questions about 
over-reporting of microcephaly during the Zika outbreak (32). However, 33% of 
infants with head circumferences between 2 and 3 standard deviations below the 
mean have moderate to severe intellectual impairment, which serves as some 
justification for use of a less selective definition (33).  
The Brazil outbreak was the first time that microcephaly was reported in 
connection with ZIKV, despite the fact that the virus is endemic in Africa. This 
perhaps is due to the fact that, as a middle-income country, Brazil is far more 
capable of monitoring and reporting cases of microcephaly than the majority of 
countries in Africa. Additionally, while WHO predicts 4 million cases in Brazil 
alone, the largest outbreak in Africa perhaps impacted too few people to see a 
noticeable spike in microcephaly cases (34). Other explanations have to do with 
the nature of the virus—it could have become more neurovirulent as it travelled 
through the Polynesian islands, or in general the Asian strain could be more 
neurovirulent than the African strain.  Given that this is the first time 
microcephaly has been seen in conjunction with ZIKV, it is important to establish 
the link between ZIKV and microcephaly despite the low risk of congenital 
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microcephaly because many people are at risk for exposure, there is a high 
incidence of ZIKV, and the burden of microcephaly is high (33).  
As of June 25, 2016, there were 8165 reports of microcephaly in Brazil with 
1638 (32%) confirmed as linked to ZIKV (33). Worldwide, as of December 7 2016, 
there have been 2499 reported cases of microcephaly or central nervous system 
malformation possibly associated with ZIKV from 29 countries and territories 
(35). Researchers believe that the risk of congenital ZIKV syndrome is greatest 
earlier in pregnancy. Currently, the risk of microcephaly during a first trimester 
infection with ZIKV ranges from 0.88%, assuming an 80% overall ZIKV infection 
rate and 100% over-reporting of microcephaly cases, to 13.2% when assuming a 
10% ZIKV infection rate and no over-reporting. The lower assessment is similar 
to the 1% risk retrospectively reported from the French Polynesian outbreak (32). 
Within the U.S., the CDC has estimated that among pregnant women with 
laboratory evidence of ZIKV infection, 6% of fetuses and infants have birth 
defects potentially related to the infection, and among women with first trimester 
ZIKV infection that number rises to 11% (36).  
 Shepard’s Criteria for Proof of Teratogenity can be applied to examine the 
link between ZIKV and microcephaly. The criteria are the following: proven 
exposure to the agent at one or more critical times during prenatal development; 
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consistent findings by two or more high-quality epidemiologic studies; careful 
delineation of clinical cases; a rare environmental exposure that is associated 
with rare defect; and the association should make biologic sense. Causality is 
established via the “rare exposure-rare defect” approach if there is proven 
exposure to the agent, careful delineation of clinical cases, and rare 
environmental exposure with rare defect (37). 
Proven exposure to the agent at one or more critical times during prenatal development   
 The most severe cases of microcephaly have been linked to maternal ZIKV 
infection during the first trimester or early second trimester of pregnancy, as 
established by the timing of travel to an area with endemic ZIKV or by the 
timing of symptoms. Infections later in pregnancy have been associated with 
poor intrauterine growth, fetal death, or defects present in prenatal screening 
(37).  
Careful delineation of clinical cases 
The phenotype for infants with congenital defects has been well 
characterized. In addition to microcephaly, newborns of women infected with 
the ZIKV have the following malformations: cerebral and placental calcifications, 
oligohydramnios or anhydramios; agenesis of corpus callosum, agyria; 
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hydrocephalus; ventriculomegaly; brain atrophy; hydrops fetalis; arthogrypossi; 
and macular choriorentinits. Additionally, about 30% of children with suspected 
ZIKV infection in utero have significant retinal and optic nerve abnormalities. 
These findings have led some researchers to refer to the “congenital Zika 
syndrome” (6).  
Rare environmental exposure with rare defect 
A rare exposure during pregnancy, linked to a rare defect, is considered a 
criterion of causality because of the low probability that both events would occur 
separately. Microcephaly is considered a rare defect, occurring in about 6 infants 
per 10,000 livebirths in the U.S. While ZIKV is not a rare environmental exposure 
in areas with endemic ZIKV, travelers returning from areas where it is endemic 
serve as an example of a rare environmental exposure (37). Case reports include 
a Finnish woman in her 11th week of gestation who was on holiday in Mexico, 
Guatemala and Belize, tested positive for IgM and IgG antibodies against ZIKV, 
and showed a decrease in fetal head circumference size from 47th percentile to 
24th percentile between the 16th and 24th week of gestation (38); reports from the 
CDC of nine pregnant U.S. women traveling to areas with endemic ZIKV out of 
which there were two early pregnancy losses and a live birth with severe 
microcephaly (39); and a European women who became ill while in Rio de 
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Janeiro during her 13th week of pregnancy, whose fetus was found to have 
confirmed delayed growth, neural abnormalities, and microcephaly in the 32nd 
week of gestation (40). 
Biological sense  
The above three criteria are sufficient proof of causation under the “rare 
exposure-rare defect” approach of Shepard’s criteria for teratogenicity. However, 
examining whether the association makes biological sense will further establish 
the link between microcephaly and ZIKV. Primary microcephaly results mainly 
from the depletion of neural stem/progenitor cells, which can be caused by 
centrosomal defects, premature differentiation, and/or cell death. Although ZIKV 
has been shown to preferentially infect human pluripotent stem cell-derived 
neural progenitors and organoids, and cause mitotic impairment and cell death 
in mice, this does not necessarily mean that the same process occurs in humans 
given the unique nature of the human CNS. Thus, while it seems as though 
ZIKV-induced microcephaly is caused by direct infection of the neural cells, 
there also appears to be some role of indirect consequences of the infection, such 
as inflammation and altered placental support (13, 41).  
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One study by Onorati et al. supported the former explanation when 
comparing neuroepithelial cells (NES), 
organotypic fetal brain slices, and the 
postmortem human tissue in the context of 
ZIKV infection since it was found that NES 
and radial glial cells (RGC) are infected, 
mitotically impaired, gain supernumerary 
centrosomes and structural disorganization, 
and killed by ZIKV (Figure 7). The study also examined the impact on TANK-
binding kinase 1 (TBK1), a cellular serine-threonine kinase that is essential for 
antiviral immune signaling and cell proliferation. After phosphorylating TBK1, it 
was found that phosphorylated TBK1 (pTBK1) localized to the centrosome in 
NES and neurocortical cells and RGCs of organotype brain slices. However, 
pTBK1 was not detected in centrosomes of ZIKV-infected cells, but was instead 
localized to the mitochondria. The inhibition of TBK1 led to mitotic defects and 
supernumerary centrosomes since it was diverted away from mitosis and 
towards innate cell signaling (14). 
Another possible explanation for the cause of microcephaly involves the 
role of the retinoic acid response element (RARE). Retinoic acid, a small non-
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peptide lipophilic molecule, gets taken up into the nucleus by the cellular 
retinoic acid binding protein where it binds to retinoic acid receptors (RAR and 
RXR) on the promoter regions of specific genes. RAR and RXR are important 
transcription factors that influence RARE consensus sequences in many genes 
involved with neural tube development, as well as playing a role in activating 
other regulatory molecules involved in neural tube formation and brain 
development. Retinoic acid is involved in determining the neural axis, is the 
prime determinant of the anteroposterior axis, and plays a role in establishing 
the anterio-posterior axis (40).  
When ZIKV gets integrated into the host DNA, and the inserted DNA 
sequences of the virus match the regulatory regions of the host genes, as is the 
case with ZIKV, the expression of these genes can be disrupted. The RARE 
consensus sequence (5’-AGGTCA-3’) is found in most ZIKV strains, with 
different frequencies depending on the strain; the strain implicated in the recent 
outbreak in Brazil had the highest number of RARE sequence repeats. 
Additionally, the only other viruses that contain the RARE consensus sequence 
are known to either cause fetal brain malformation or show neurotropism, with 
the number of repeats seemingly proportionate to the potency of the virus as a 
teratogen or the degree to which it shows neurotropism. Some of these are 
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specifically known to cause fetal microcephaly, such as CHIKV, HIV, rubella, 
herpes simplex virus-2, and varicella zoster virus (40).  
The effect of retinoic acid dysregulation also make sense in light of the 
differences in fetal malformation. If the woman becomes infected during late 
gastrulation or early neuralation stage, which spans from the first to the early 
second trimester, the defect should occur during the rostrocaudal sequencing of 
the brain, causing a larger hindbrain at the expense of anterior brain structures. 
However, if infection occurs during late developmental stages, the dorsalization 
of the brain or the hindbrain structures will be affected, resulting in cerebellar or 
brain stem hypoplasia or absence of some hind brain components. Reports of 
women who presented with ZIKV-like symptoms during their 10th week of 
gestation would face disruption of the development of dorsal brain structure and 
hindbrain structure; this would result in the features typically seen in ZIKV 
microcephaly (40).  
While these studies have demonstrated several possible ways that 
infection with ZIKV could cause microcephaly, there appears to be some 
difference in how the virus behaves based on whether the patient is infected with 
the African or Asian strain. One study found that both strains cause cell death, 
but only the Asian strain, which is more closely related to the strain causing the 
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current epidemic, induced specific dysregulation of DNA replication and repair 
genes and the upregulation of viral response genes involved in interferon 
response, Type II interferon signaling, Toll-like receptor signaling, and TNF(a) 
signaling pathways in hNPCs (4).  
In an effort to better elucidate the link between ZIKV and microcephaly, 
ZIKV was compared to the dengue virus 2 (DENV2) since these viruses are 
overall very similar, but DENV2 does not seem to cause the same effects on 
fetuses. While it appears that DENV2 can also infect hNPCs, it does not seem to 
have the same impact on their proliferation, the morphology of the neurosphere, 
or the growth of brain organoids. Rather, any changes seen with DENV2 were 
caused more by inflammatory response (4). Although ZIKV differs from DENV2 
in this respect, other flaviviruses are known to be neuropathic, namely WNV, 
JEV, St. Louis encephalitis, and TBEV, and so could be used to help delineate the 
mechanism by which ZIKV causes microcephaly (43). There are also some non-
flaviviruses that can lead to neural changes similar to those caused by ZIKV: 
rubella and cytomegalovirus can cause microcephaly, and rubella also causes 
cerebral calcifications, as described with ZIKV (33).  
	 28	
Guillain-Barré Syndrome 
 Guillain-Barre Syndrome is an immune-mediated disease affecting the 
peripheral nervous system that can lead to severe neuropathy causing muscular 
paralysis and occasionally resulting in death (33). The link between GBS and 
ZIKV is less well established than between ZIKV and microcephaly, with most of 
the evidence coming from the 2013 French Polynesian outbreak where two 
different studies retrospectively found that the risk of developing GBS had 
increased >34-fold (44). In the first study, 42 patients with GBS and a history of a 
recent viral syndrome were tested for ZIKV using RT-PCR at time of admission. 
All the samples with one exception were negative for ZIKV. However, when 
later tested with IgM, IgG, or neutralization tests all were found to be positive for 
ZIKV, although this was up to three months post-hospitalization so could have 
been due to a subsequent infection. A second study used the same 42 patients 
with confirmed GBS, then collected serum from 98 matched controls hospitalized 
with non-febrile illness within 7 days of admitting the matched GBS case. In this 
instance, while all 42 GBS patients had neutralizing antibody for ZIKV, only 
54/98 (56%) of the control patients had neutralizing antibody (1). No association 
was observed between the occurrence of GBS and history of DENV infection, 
	 29	
which suggests that DENV neither provided immune enhancement nor immune 
protection for ZIKV infection (6). 
 There are two possible mechanisms that explain the association between 
ZIKV and GBS. The first is that ZIKV triggers an autoimmune response due to 
molecular mimicry between ZIKV and naturally occurring glycolipids on host 
cells. The second possibility is viral neurotoxicity, which is favored given the 
rapid onset of neurological symptoms after symptoms consistent with ZIKV 
infection (45).   
Interventions 
Although a relatively small percentage of people experience the more 
drastic effects of ZIKV (congenital Zika syndrome, GBS, death), the high 
incidence rate of ZIKV and the large number of people living in regions where 
they could be exposed (around 2.17 billion) make it potentially devastating—
WHO predicts up to 4 million cases of ZIKV in the Americas alone. Not only are 
there many people at risk for exposure to ZIKV, but ZIKV is a disease of poverty: 
while everyone is susceptible to mosquito bites, those of a lower socioeconomic 
status (SES) will likely be predominately affected since poor neighborhoods often 
have limited urban infrastructure with sporadic water and infrequent waste 
collection. This means that people in these neighborhoods store water, which 
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serves as potential breeding sites for mosquitoes, or have discarded containers 
and organic waste in their yards, which also increase the density of the mosquito 
population. Those of a lower SES are also less likely to be able to afford mosquito 
repellant, protective clothing, mosquito nets, and air conditioning. The link 
between ZIKV and poverty can be seen in Brazil, where the ZIKV outbreak is 
concentrated in the north and northeast regions of Brazil, the poorest area of the 
country (46).  
The link between ZIKV and poverty is particularly worrisome given the 
nature of congenital microcephaly, which is associated with intellectual 
impairment, seizures, visual and hearing impairment, feeding difficulties, and 
significant developmental delay. Thus, a child with microcephaly places a 
significant financial burden on families—one study calculated that, in the U.S., a 
lifetime of expenses would be around $179,760 (47). However, it also impacts the 
development of the country through its effect on disability adjusted life years 
(DALYs). ZIKV is often compared to DENV, with the belief that DENV is of 
greater concern since it has a higher incidence in Brazil. However, when 
combining the effect of microcephaly and GBS, estimates of DALYs lost due to 
ZIKV infection range from 43,717 to 108,951 (assuming an attack rate of 5%) to 
349,738 to 871,610 (assuming an attack rate of 40%). In comparison, the burden 
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from DENV is a loss of 89,500 DALYs in Latin America and the Caribbean (47). 
Thus, although the incidence of DENV is far higher than that of ZIKV, ZIKV has 
the potential to negatively impact the public health of Brazil to a far greater 
degree. 
Estimates of costs of caring for a child with microcephaly and lost DALYs 
only capture the visible impact of ZIKV. It is believed that children whose 
mothers were infected with ZIKV during pregnancy but are not born with 
microcephaly might experience the negative effects of congenital ZIKV 
syndrome to some degree, so the actual burden of ZIKV will only become 
apparent as these children begin to show symptoms (33). Additionally, there is 
an increasing amount of evidence linking ZIKV to miscarriages and stillbirths: 
the virus has been identified in the brains of stillborn children with 
microcephaly, suggesting that it may be responsible for early pregnancy loss  
(48). If this were the case, the burden of the disease on public health would be 
even greater than the current estimates. The following interventions are designed 
to reduce the effects of ZIKV through targeting the virus, reducing vector and 
sexual transmission, and decreasing the number of unwanted pregnancies that 
result in children with microcephaly.  
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Monoclonal antibodies 
 While researchers are moving towards developing a ZIKV-specific 
vaccine, certain high-risk individuals, such as exposed pregnant women, 
immunocompromised patients, or those with severe ZIKV disease, are left 
exposed. One option would be to use monoclonal antibodies as either 
prophylaxis or treatment. Recent studies in mouse models have shown that 
isolated monoclonal antibodies neutralize ZIKV and offer protection by targeting 
epitopes on the E protein and on infectious virions. Additionally, a category of 
DENV monoclonal antibodies isolated from DENV patients could cross-
neutralize ZIKV through targeting quaternary epitopes at the interface between 
two subunits of the E protein dimer (6). 
Antiviral Drugs 
 Currently no commercially available treatments are successful against 
members of the flavivirus genus. However, several drugs already on the market 
seem to have an effect against ZIKV, like the nucleoside analogue sofosbuvir, 
which is approved for treatment of hepatitis C virus (HCV) infection. Sofosbuvir 
inhibits RdRp activity, a domain located at the C-terminus. RdRp is an attractive 
option for antiviral treatment because human cells lack RdRp activity, so 
inhibition of this domain causes comparatively few side effects. Infectivity of 
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both the African strain and the strain responsible for the outbreak in the 
Americas was inhibited to a similar degree by sofosbuvir in vitro. Some resistance 
to sofosbuvir has been reported, but it has been slower to develop than inhibitors 
of other HCV proteins (17). 
Other than resistance, one of the biggest concerns with any treatment for 
ZIKV is fetal safety. Animal studies with sofosbuvir have not revealed any fetal 
harm, but there have been no controlled studies with human pregnancy. 
Sofosbuvir is currently classified as category B, i.e. no known risks for pregnant 
women but should only be used when no other treatment options are available. 
However, it could be used prophylactically, among non-pregnant women, or in 
men to decrease likelihood of sexual transmission. Using it in all of these 
populations will diminish viremia disrupting the infection cycle with the Ae. 
aegypti mosquitoes (17).  
 Another group of researchers used a drug re-purposing screen in order to 
accelerate the process of finding a treatment for ZIKV. Xu et al. chose to use 
caspase-3 activity as a primary assay with a secondary assay of cell viability since 
previous findings indicated that ZIKV infection of hNPCs caused increased 
caspase-3 activation, followed by cell death (49). Two classes of effective 
compounds were found that could protect neural cells from ZIKV-induced 
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death: antiviral and neuroprogenitive. Within the antiviral class, one group was 
ten structurally unrelated cyclin-dependent kinase inhibitors (CDKi). While these 
may not be suitable for pregnant women given the known hazards, they have 
potential use for treating non-pregnant individuals at increased risk of GBS, or 
those who might infect a pregnant woman through sexual transmission. 
Niclosamide, an FDA-approved drug for treating worm infections, was also 
found to be effective against ZIKV. It has a broad antiviral activity perhaps due 
to its ability to neutralize endolysosomal pH and interfere with pH-dependent 
membrane fusion, an essential step in permitting viral entry. It also might be 
effective at a post-entry step. Like sofosbuvir, it is a WHO-classified type B drug 
(49). Emricasan, a pan-caspase inhibitor currently in Phase 2 trials for use against 
HCV, falls within the neuroprogenitive class of drugs but does not prevent ZIKV 
from replicating. Xu et al. tested it in combination with niclosamide, and 
sequentially with PHA-690509, one of the CDKi’s. In both cases, emricasan 
appeared to be additively effective against ZIKV (49). 
Vaccines 
 The abovementioned antiviral drugs all exist as definitive possibilities to 
protect vulnerable individuals from ZIKV transmission and reduce the incidence 
of microcephaly. However, there are questions about the safety of these drugs for 
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pregnant women and many are prohibitively expensive: for example, sofosbuvir 
currently costs $84,000 for a 12-week regimen to treat HCV infection (18). 
Vaccine development and distribution would thus be the most effective way to 
combat ZIKV outbreaks. Development of a ZIKV vaccine seems feasible since 
vaccines exist against other flaviviruses: yellow fever virus (YFV), tick-borne 
encephalitis virus (TBEV), Japanese encephalitis virus (JEV), and DENV all have 
vaccines (20). Also encouraging for the development of a ZIKV vaccine is that it 
appears to have only one serotype (despite having two lineages) so a monovalent 
vaccine would likely cover all circulating ZIKV strains (50). However, evaluating 
the effectiveness of a ZIKV vaccine could be complicated since it has a low 
incidence and a short period of viremia. There are also safety concerns due to the 
risk of microcephaly with congenital ZIKV, a risk of sexual transmission, the risk 
of antibody-dependent enhancement with DENV or YFV, and a risk of a 
potential link between ZIKV and GBS (1). 
 When developing the ZIKV vaccine, factors to consider include the target 
population, the number of doses required to induce an immune response, the 
effect of previous flavivirus exposure on ZIKV vaccine safety and 
immunogenicity, and previous human exposure to related vaccines. The most 
critical target population for ZIKV is women of child-bearing age. Therefore, in 
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the setting of an outbreak, women of child-bearing age and/or pregnant women 
in a ZIKV-endemic area would be prioritized to receive the vaccine. However, 
preventing congenital Zika syndrome through vaccination carries unique 
challenges since only killed or subunit protein vaccines are known to be safe for 
pregnant women: live vaccines pose a known safety risk, and there is insufficient 
data about DNA vaccines, RNA vaccines, or vectored vaccines. Outside of an 
outbreak setting, the target population would include all infants and children, 
and so a vaccine would need to be safe for this population as well. Another 
consideration for ZIKV vaccine 
development, the number of doses, 
is impacted by the target 
population since the highest risk 
for congenital microcephaly occurs 
during the first trimester, so the vaccine would need to provide immunity 
quickly and following a minimum number of doses. A vaccine that is effective 
after a minimum number of doses would also have more success in curtailing 
any future outbreaks (1). 
 Another consideration relates to the concern about antibody-dependent 
enhancement of infection. This is known to occur with DENV: antibodies to one 
Figure 8. Internalization of a ZIKV virion into a 
macrophage (50). 
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DENV serotype cross-react with a different DENV serotype, allowing the virus to 
enter monocytes and macrophages through the Fc𝛾 receptor (Figure 8) (1). 
Currently, how sequential or previous infection with other flaviviruses affects 
ZIKV infection and disease is not fully understood and recent studies have 
produced conflicting results. Four studies showed that anti-DENV human 
monoclonal antibodies as well as DENV immune sera poorly neutralized and 
instead enhanced ZIKV infection in FcRII-bearing cells. A different study showed 
that DENV cross-neutralizing envelope dimer epitope 1 monoclonal antibody 
strongly neutralized ZIKV and prevented infection in human immune cells, but 
both convalescent primary and secondary DENV immune sera poorly 
neutralized DENV (50).  Clinical trials will be necessary to determine if the 
effects of vaccine-induced antibodies differ from naturally produced antibodies. 
Phase 3 trials will also be needed to determine if there are differences between 
short and long term safety and efficacy of candidate ZIKV vaccines depending 
on flavivirus serotype at the time of vaccination (1).   
In addition to developing a vaccine that is safe for pregnant women and 
does not react with other flaviviruses, there is the question of how to measure a 
ZIKV vaccine’s efficacy within the population. Although microcephaly causes 
the greatest morbidity, prevention of microcephaly is unlikely to be a suitable 
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endpoint since it would require a large sample size given that it occurs at a low 
rate, and that it can only be measured in women of a childbearing age (1). 
Furthermore, it would require a long study period before results were available 
(50).  
Prevention of clinical disease or clinical infection would be another 
possible endpoint, and would perhaps play a role in judging the reduction of 
microcephaly if viremia, symptoms, and transmission to infants are all linked. 
However, it would also be a difficult endpoint given the low frequency with 
which those infected are symptomatic. If so, since fever was reported in only 28-
73% of cases (objectively or subjectively), rash would perhaps be a better 
indicator of which cases should be tested for ZIKV. This method would require a 
much smaller sample than using microcephaly as an endpoint (1). 
Another possible endpoint to measure efficacy would be the ability of the 
vaccine to induce neutralizing antibodies in flavivirus-naïve individuals, 
particularly against the E protein on the surface of virions (20). Using 
immunogenicity is advantageous since it is easily measured, does not require a 
large sample size, can be collected over a short time (28 days post-vaccination), 
and could be done in a range of clinical settings. Passive protection in mice and 
rhesus monkeys was observed at relatively low antibody titers, likely achievable 
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in humans (52). This might be the chosen endpoint if the ZIKV transmission 
declines as individuals become less susceptible, as was the case with the WNV 
(1). However, there are disadvantages to this method: the assay has limitations, 
there is an unclear relationship between immunogenicity and protection, and 
convincing animal data is needed to establish the implications of passive 
protection (50). 
The final possible endpoint would be protection against ZIKV infection 
(as measured by seroconversion) or reduction in viremia (as measured through 
frequent blood sampling). This would represent an all-inclusive endpoint, would 
require a smaller sample, and could potentially reduce microcephaly rates if 
discovered that asymptomatic infection was relevant for congenital ZIKV 
syndrome. However, sterilizing immunity is a high bar for vaccine success, it 
remains difficult to measure viremia, and frequent sampling might be needed 
from participants to detect viremia (50).  
 In addition to the above considerations, there is also the question of 
platform choice. Vaccines from various platforms have been found to offer 
protection: purified inactivated virus adjuvanted with alum (PIV), recombinant 
envelope protein, three different plasmid DNA constructs that all encode ZIKV 
prM/E genes, and two adenoviruses expressing PrM/E genes (see Table 1). All 
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platforms induced protective immunity and passive protection in mice and non-
human primates with at least one of the regimens investigated (48). Currently 
there are three vaccine candidates with U.S. Food and Drug Administration 
(FDA) investigational allowance for human Phase 1 study, including one in an 
affected area. Two are DNA plasmid vaccine encoding for PrM and E proteins 
and one is a purified inactivated vaccine. Another DNA vaccine, GLS-5700, is 
also about to start Phase 1 trials (1). 
One vaccine currently in Phase 1 was developed by Dowd et al. using a 
PrM-E sequence from the French Polynesian strain with CMV as a vector. When 
tested on a group of rhesus macaques using a 2-dose regimen, neutralizing 
antibodies were detected and all but one macaque were protected from viremia. 
Single dose regimens were not found to be protective. An important additional 
finding from a retrospective study conducted on the same group of monkeys 
revealed that there was no evidence of disease enhancement in the monkeys that 
had previously been exposed to flaviviruses (53).  
 Abbink et al compared a plasmid DNA vaccine (GLS-5700) with one 
based on adenovirus serotype 52 (RhAd52), both tested in 12 rhesus monkeys. 
The plasmid vaccine caused the monkeys to express PrM-Env antigens at weeks 
0 and 4, while the RhAd52 vaccine caused expression after a single immunization 
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at week 0. Both groups of animals were also tested for ZIKV-specific neutralizing 
titers: animals who had been vaccinated with the plasmid DNA had minimal 
levels detected at week 0 although they were detected after the week-4 booster 
while monkeys vaccinated with RhAd52 had antibodies detected 2 weeks after 
the initial priming immunization. Additionally, there was a substantial breadth 
of antibody response against linear ZIKV envelope epitopes detected with the 
RhAd52 vaccine (52). Both of these vaccines were also found to offer complete 
protection against subcutaneous challenge with 105 virus particles in Balb/c mice 
using either one of two wild type ZIKV strains of Asian lineage. They also 
showed that protection can be mediated by antibody alone, and that protection 
was correlated with the magnitude of the antibody response (54).   
The same researchers tested a PIV, now in Phase 1 trials, in 16 rhesus 
monkeys. All the monkeys developed ZIKV envelope-specific binding antibodies 
(detected using ELISA) and neutralizing antibodies (detected using 
microneutralization). Antibody titers increased after a week-4 booster. When 
compared to rhesus monkeys given a sham vaccination, the sham monkeys after 
6-7 days had virus detected in the blood, urine, cerebrospinal fluid, colorectal 
secretions, and cervicovaginal secretions while those vaccinated with the PIV 
had no virus detected. Semen from the monkeys could not be tested due to 
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insufficient sample size. Additionally, purified IgG from the vaccinated monkeys 
provided passive protection to both rodents and primates. Although the PIV 
offered equal protection as the plasmid DNA vaccine and the RhAd52 vaccine in 
mice, the PIV vaccine was more potent in rhesus monkeys (48).  
 Larocca et al. used isolate from northeast Brazil and Puerto Rico to make a 
PrM-Env DNA vaccine given intramuscularly (im) to Balb/c mice as a single 
immunization of 50 𝜇g at week 0 with antibody response evaluated by ELISA at 
week 3. The prM-Env DNA vaccine was found to elicit high Env-specific titers, 
induce ZIKV-specific neutralizing antibodies after one immunization, and induce 
Env-specific CD8+ and CD4+ T-cell responses. At week 4, both vaccinated and 
sham-control mice were infected. Sham-control mice developed viremia after 
approximately 6 days while the vaccinated mice had complete protection against 
ZIKV after one vaccination. The protection remained when the mice were 
challenged at week 8, and when challenged with the strain responsible for the 
Puerto Rico outbreak, ZIKV-PR (48).  
 Larocca et al. compared the DNA vaccine to a PIV vaccine derived from 
the Puerto Rico strain. Groups of Balb/c mice received a single immunization im 
or subcutaneously (sc). The im route produced higher antibody titers and 
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provided complete protection for the mice when challenged with ZIKV, while 
the two mice that received the injection sc had brief periods of viremia (52). 
 Muthumani et al. tested a ZIKV-PrME consensus vaccine that was 
delivered via electroporation by the intradermal route in a three-dose regimen to 
C57BL/6 and IFNAR-/- (immunocompromised) mice, which was found to 
produce a robust humoral immune response. A single vaccination was protective 
against challenge in IFNAR-/- mice: when infected with ZIKV, 100% survived 
after three weeks compared to only 10% of the controls. Additionally, when 
brain samples were compared, researchers found that the mice who had been 
vaccinated had normal brain histopathology while mice who had not been 
vaccinated had brain sections with nuclear fragments within neutrophils, 
perivascular cuffing of vessels within the cortex, lymphocyte infiltration and 
degenerating cells of the cerebral cortex, and degenerating neurons within the 
hippocampus (55). The same researchers also tested their vaccine by immunizing 
rhesus monkeys via the intradermal route in a 2-dose regimen, which produced a 
robust cellular and humoral immune response and produced neutralizing 
antibodies (48,55). 
Another group of researchers compared a recombinant adenoviral vector 
expressing codon-optimized ZIKV E antigen (Ad5.ZIKV-Efl) and a subunit 
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recombinant ZIKV E vaccine (MNA-ZIKV-rEfl) in mice by testing the anti-ZIKV 
humoral immune response through looking at antibodies to the E antigen (using 
ELISA) and neutralizing titers (using PRNT50). Overall the adenovirus vaccine 
was more potent and more effective: there were antibodies detected 2 weeks 
after a single dose compared to 4 weeks after a booster, and it was more efficient 
against protecting neonatal mice against ZIKV challenge. Additionally, after 
vaccinated dams were challenged with ZIKV, some pups born to the mother of 
the subunit vaccine had neurological illness (although less severe than seen in 
the controls); those born to the mother vaccinated with Ad5.ZIKV-Efl had mild 
to no neurological illness or symptoms. However, Ad5.ZIKV-Efl is less likely to 
be used in humans due to the prevalence of anti-adenovirus serotype 5 
neutralizing antibodies. Both vaccines, when given to dams, protected pups 
against ZIKV challenge on day 7 (56). 
Lastly, there is a live attenuated vaccine (LAV) based on the nonstructural 
protein components of a LAV for DENV but containing the PrM and E subunits 
of ZIKV. The DENV vaccine is currently in Phase 3 trials; if the ZIKV vaccine is 
immunogenic there are hopes to combine the two vaccines to create a 
pentavalent vaccine that could be given to children who live in a region where 
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DENV and ZIKV are endemic.  It is unlikely to be deemed safe for pregnant 
women (57,58).  
 
Table 1. ZIKV vaccine development. Vaccines currently in Phase 1 trials are 
marked with an asterisk 
Study 
author Type Doses Test Result 
Dowd* 
PrM-E with 
CMV as 
vector 
 
2 doses 
(week 0 
and 4) 
6 rhesus 
monkeys 
vaccinated 
Neutralizing antibodies in 
all vaccinated 
No viremia in all but one 
vaccinated 
Abbink* Plasmid DNA 
2 doses 
(week 0 
and 4) 
12 rhesus 
vaccinated 
Antibodies from 
monkeys given to 
Balb/c mice  
PrM-E antigens in 
vaccinated 
ZIKV-specific neutralizing 
Abs after booster 
Abs protected mice  
Abbink 
Adeno-
serotype 1 dose 
12 rhesus 
vaccinated 
Antibodies from 
monkeys given to 
Balb/c mice 
PrM-E antigens in 
vaccinated 
ZIKV-specific neutralizing 
Abs after single dose 
Abs protected mice  
Abbink* PIV 
2 doses 
(week 0 
and 4) 
Tested 16 rhesus 
monkeys 
 
Developed ZIKV envelope 
specific binding 
antibodies and 
neutralizing antibodies; 
increased after booster 
No virus detected in 
secretions  
Purified IgG offered 
passive protection 
Larocca PrM-E DNA 1 dose 
Mice vaccinated 
and subsequently 
challenged 
High E-specific titers, 
induced ZIKV-specific 
neutralizing antibodies 
after one immunization, 
and induce E-specific 
CD8+ and CD4+ T-cell 
responses 
Protected after challenge 
at week-4, week-8, and 
with a different strain 
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Larocca PIV 1 dose  
Mice vaccinated 
im or sc 
Im produced higher 
antibody titers and 
provided complete 
protection against viremia 
Muthumani  
PrM-E 
consensus 
3 doses 
via 
electro-
poration 
(week 0, 
2, 4) 
Used on immuno-
compromised 
mice 
Rhesus monkeys 
Robust humoral response 
1 dose protected against 
challenge in 
immunocompromised 
2-dose in monkeys 
produced robust humoral 
and cellular response, 
and neutralizing 
antibodies 
Kim 
Recombinant 
adenovirus 
1 dose, 
booster 
after 2 
weeks 
Mice vaccinated 
Pups of 
vaccinated 
mothers tested  
Antibodies detected after 
booster 
0/10 pups developed 
neurologic disease 
Pups of vaccinated dam 
protected when 
challenged on day 7 
Kim 
Subunit 
recombinant 
E 
1 dose, 
booster 
after 2 
weeks 
Mice vaccinated 
Pups of 
vaccinated 
mothers tested 
Antibodies detected after 
booster 
Mild neurologic illness in 
pups when mother was 
challenged in 5/6 pups 
Dams of vaccinated 
mother protected when 
challenged on day 7 
 
Anti-vector strategies 
 Brazil already faces challenges from vector-borne diseases, with 1.4 
million cases of DENV reported in Brazil in 2015, resulting in a loss of around 
200 disability-adjusted life years (DALYs) per million  (59,60). The high incidence 
of DENV, along with the presence of other vector-borne diseases, means that the 
government and local communities already employ many strategies aimed at 
reducing the population of the Aedes mosquito, which acts as a vector for both 
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DENV and ZIKV. Aedes genus is particularly difficult to control given that it can 
adapt to breeding in urban and rural areas, its laid eggs can survive for long 
periods of time in a dry state then hatch immediately once submerged in water, 
and during cool temperatures, the mosquitoes remain larvae so long as there is a 
sufficient water supply (61). The strategies have achieved varying degrees of 
success; however, in the setting of a resource-constrained country like Brazil, it is 
essential that chosen interventions effectively and efficiently reduce the mosquito 
population. Presently, increased vigilance is required due to the current ZIKV 
epidemic, the threat of CHIKV, and a growing range of the Aedes mosquito due 
to climate change (62,63). 
Improved surveillance   
Key to introducing efficient reforms is accurately monitoring the Ae. 
aegypti population. In 2004, aiming to reduce DENV transmission, the Brazilian 
government introduced a strategy to rapidly identify mosquito breeding sites 
called Levantamento Rapido de Ince para Ae. aegypti (LIRA) as a more 
streamlined surveillance approach for large urban settings. However, the success 
of the program has been mixed: although it has achieved regular and systematic 
monitoring of mosquito populations with low infestation indices, the 
transmission rate remains high. In 2011 a pupal production study was launched 
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in Goiana, Goiás, to determine the actual mosquito population. It concluded that 
there were higher levels of immature mosquito infestation than detected by LIRA 
and that three types of containers produced 70% of all pupae: water-holding 
roofs, roof top gutters, and elevated water tanks. These containers all share the 
feature of inaccessibility, making it likely that they were overlooked by rapid 
surveillance. This oversight explains why current control activities are perhaps 
not reaching their full potential, and explains the discrepancy between the low 
reported infestation indices and the high rates of ZIKV transmission. This is 
especially true since Aedes mosquito production can be highly concentrated, 
allowing them to survive, without a reduction in number, in less accessible 
spaces once more accessible breeding sites are removed or destroyed (64). 
One strategy that has been employed by the state of Bahia to increase 
surveillance makes use of the approximately 57.8 million residents of Brazil with 
smartphones (65). “O caça mosquito”, or “the hunt for mosquitoes”, is an app 
that allows citizens to photograph and alert officials about mosquito breeding 
sites. The Bahia Department of Health then localizes the breeding site and 
contacts local organizations who eliminate it. The government, through receiving 
multiple reports, can map zones where breeding sites for mosquitoes are 
common (66). Interventions such as this will hopefully allow the government to 
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accurately assess the mosquito population and locate prime breeding spots so as 
to most effectively eliminate disease transmission.  
Insecticide 
 The Brazilian pesticide market (insecticides and larvicides) has rapidly 
grown in response to the threat of DENV (also spurred on by agricultural 
demands): after beginning to use insecticides in 1986, by 2008 Brazil topped the 
world rank in pesticide use. Even though the use of pesticides has been largely 
unsuccessful in the fight against DENV—the incidence of DENV has increased 
markedly from 1990 to 2015—the government has redoubled the use of 
pesticides in order to combat ZIKV though mobilizing armed forces to survey 
households, adding larvicides to the water supply, and thermos-nebulisation of 
malathion (67).  
 Not only is pesticide use ineffective, it has several serious downsides. The 
greatest is perhaps mosquito resistance: WHO now considers resistance as a 
major threat for diseases transmitted by mosquitoes, and believes that it has 
contributed to the reemergence and/or spread of arboviruses (68).  In Brazil, one 
study examined the resistance of the Aedes mosquito in the aftermath of a 2010 
DENV outbreak in Boa Vista, Roraima, during which standard vector control 
measures were intensified. Despite increased use of insecticide, only a slight 
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decrease in vector density was detected due to high resistance. In fact, increased 
spraying was counterproductive since it created a false sense of security within 
the community so that people were less aggressive in using other methods of 
vector control (i). Additionally, the intensification of vector control resulted in a 
dramatic increase in vector resistance. Before the study began there were 
resistance ratios1 of 10-15; three months later values hovered around 30, and by 
six months they were at 40-50. The heterogeneity of the mosquito sample also 
decreased (70). 
Another study in Rio de Jaineiro looked at resistance based on whether 
the insecticide targeted larvae or adult populations. Larval control has an 
environmental prevalence of two months, during which time the effectiveness of 
the insecticide wanes. Adult control has an immediate effect which lasts for one 
day. Both adult and larval control interventions range from one to six 
applications per year, and also range in efficacy, with those that achieve above 
90% mortality considered highly effective. After examining the use of both types 
of sustained insecticide use on resistance, the study found that while continuous 
larval control reduces the mosquito population, as insecticide resistance 
																																																								
1 Calculated by dividing the LD50 of the resistant population by the LD50 of the 
susceptible population 
	 51	
increases the mosquito population recovers. Additionally, during the initial years 
in which the mosquito population is dwindling, the community loses herd 
immunity, a phenomenon that has been associated with an increased magnitude 
in the eventual DENV outbreak and might also be seen with ZIKV. This same 
study noted that most studies assessing field-based efficacy of adult and larval 
control were from two decades ago, and that the efficacy of insecticides differs 
greatly between the laboratory and the wild (60). In the context of the ZIKV 
outbreak further research is needed. 
Pesticide spraying carries other negative consequences: there are over 
7000 reported deaths annually from pesticide poisoning in Brazil, about 60% of 
which are estimated to be due to insecticides, with many more cases believed to 
be unreported (71). Furthermore, there is damage to the environment; and 
insecticides are non-specific, leading to the death of other insects with 
unintended and unanticipated environmental effects (72). Additionally, such 
measures are inefficient since they often fail to target the poorest households, 
which are outside the formal water supply and so do not receive treated water, 
or are outside the area monitored and sprayed by the armed forces. Given the 
extreme negative consequences of widespread insecticide use and its overall 
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inefficiency, insecticide spraying should be used sparingly, only in emergency 
settings, and never as the sole means of controlling mosquitoes (67).  
Reduction of breeding sites 
 People frequently store water due to its irregular supply, a problem 
especially common in northeastern Brazil where 40% of cities face water 
rationing, compared to 23% of cities in the country overall (73). One study chose 
to examine mosquito breeding sites in Fortaleza, Ceará, a city in northeastern 
Brazil. Fortaleza exemplifies many of the challenges found throughout the 
country: residents often rely on containers for water storage since there is no 
regular water supply, the city has undergone rapid urbanization with 
subsequent high population density, and there is a lack of a planned urban 
infrastructure (74). The survey found that 43.6% of Aedes pupae (used as a proxy 
for adults) live in containers used to store water, highlighting the effect that 
improving water supply would have on reducing ZIKV transmission.  
Another key initiative to reducing the number of mosquito breeding sites 
is to improve waste collection. Lack of regular refuse collection leads many 
Brazilian citizens to store refuse until a truck comes, dump the refuse in a vacant 
lot, or wait for an informal refuse collector. In the case of the latter, the informal 
refuse collector then stores the waste on his or her own property. Areas with 
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refuse collection every other day have a higher prevalence rate of parasitoses 
than areas with daily pick up, supporting the argument that improved waste 
collection could reduce the rates of ZIKV transmission (75). Additionally, the 
abovementioned survey in Fortaleza found that 56.4% of Aedes pupae were from 
small discarded containers not used for water storage, items that perhaps would 
have been removed if a regular refuse collection existed. 
Another possible intervention is through social participation, which is key 
to curtailing the spread of diseases like DENV and ZIKV since vector control 
requires lifestyle and household management. One intervention among 10 
clusters in Fortaleza involved establishing partnerships, meeting with 
intersectorial groups to explain the objectives and procedures of the activities in 
homes; petitioning the Regional Secretariat for a truck for waste collection; 
organizing social mobilization through groups formed by National Health 
Service professionals; and involving educators and Endemic Disease Agents to 
make home visits, deliver garbage bags, inform the community about the date on 
which the garbage truck was going to arrive, and provide general health 
information. Overall the study found a significant reduction of mosquito 
populations with an increase in people’s knowledge about disease transmission 
and willingness to participate in preventative actions. However, social 
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participation, and subsequent ability to reduce waste that allowed for 
mosquitoes to breed, varied greatly between locations based on whether 
community organization and leadership already existed (74). 
Education is also key to reducing breeding sites. Various studies have 
examined baseline knowledge about DENV in endemic areas, especially with 
regards to transmission. One study in Maríla, São Paolo found that although 
many people could identify waste as a risk factor for DENV transmission, it was 
unclear if the connection was between “dirty” waste, such as organic matter, 
versus “clean” waste, such as bottles and cans (75). Another study in Ribeirao 
Preto, São Paolo, found that many respondents misidentified the times of day 
during which mosquitoes were the most active or did not know the number of 
times DENV could be contracted, and a small number thought that DENV was 
transmitted through standing water (76). For ZIKV, a virus that is new to the 
region, it is likely that there is a greater amount of misinformation. 
Cultural Perspective   
Reforms such as improving refuse collection, community education, and 
strengthening community participation in interventions are all key to reducing 
mosquito density and subsequently decreasing the incidence of ZIKV. However, 
there are also cultural perspectives to waste treatment that cannot be overlooked, 
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particularly as to what constitutes “waste”. One study in Marília, São Paolo, 
sought to examine this aspect of vector control through surveying several 
neighborhoods with regular refuse collection and high knowledge of DENV. 
Despite knowing that containers were breeding sites for mosquitos, many 
respondents did not name items such as metal, glass, and plastic containers as 
refuse (“lixo”), since they could be sold or repurposed. Researchers noted that 
this viewpoint was associated with low-income status (75).  
Informal refuse collectors, who significantly contribute to waste removal 
in Brazil, shape this perspective. Most people have a positive impression of the 
informal refuse collectors and save items for them, some of which are possible 
larval habitats. These containers are stored by the initial owner, sometimes for 
months if waiting for the informal refuse collector to return, and then 
subsequently stored by the informal refuse collector. Although one solution 
would be to eliminate this method of waste disposal, there are thought to be over 
a quarter million waste collectors in Brazil, who would otherwise have no 
income and who overall contribute favorably to the urban economy and the 
environment. Therefore, the goal should be to involve them in any interventions 
and insure they receive training on how to separate and store containers that 
could breed mosquitoes (75,77). 
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Genetic modification 
 Despite the best efforts of many communities in countries around the world, 
achieving successful vector control remains an elusive goal, even for cities like 
Singapore that have a strong urban infrastructure and resources at their disposal. 
Researchers have explored other options like the sterile insect technique, which 
involves the release of radiation-sterilized insects who mate but produce none or 
fewer viable offspring. Trials with mosquitoes have been less successful due to 
performance reduction, so that sterilized insects mate less frequently than wild-type. 
However, scientists can now modify insects to carry a self-limiting gene that does 
not reduce performance and could be reversed in the laboratory. The gene causes 
death to the zygote, and adjusting the stage of death could allow for manipulation of 
the population density. The insects, the OX513A strain, was tested in a suburb of 
Juazeiro, Bahia. There was an effective suppression by 95% based on adult trap rates 
and 78% based on ovitrap indices when compared to no-release control areas. 
Suppression success was limited by migration of mosquitoes into the intervention 
area, so testing the OX513A strain on a wider area might produce better results, 
especially as the Aedes mosquito typically has a flying range of 25 meters, and at 
most 500, meters (63,78).  
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 Potentially the greatest downside to this approach is the cost, estimated to 
be around $1.9 million in the first year and $384,000 every subsequent year for an 
urban population of 50,000. However, in light of the burden of ZIKV and other 
mosquito-borne diseases, this might still be a cost-effective intervention in areas 
where such diseases are endemic (47). 
Use of Wolbachia  
In 1997 the Wolbachia strain of 
intracellular bacteria was discovered to have 
naturally virulent properties causing it to 
halve the lifespan of its host, Drosophila 
melanogaster. The strain has been introduced 
into Ae. aegypti and found to halve the lifespan of the mosquito by 50%, and to be 
passed maternally to 100% of the offspring (79). Additional research revealed 
two promising findings. The first was that infection with the Wolbachia bacteria 
prevented mosquitoes from carrying DENV, CHIKV, and YFV strongly 
suggesting that it could inhibit replication of ZIKV. Secondly, mosquitoes 
carrying Wolbachia are able to invade native populations since the offspring of an 
uninfected female and infected male are inviable, while the offspring of an 
infected female and either type of infected male will inherit the bacteria (Figure 
Figure 9. Use of Wolbachia to stop DENV (80). 
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9). Estimates suggest that if one strain of Wolbachia were released, it would 
reduce the basic reproductive number by 70%, substantially lowering the rate of 
DENV transmission. Studies are currently underway to test if this method will 
reduce DENV transmission in the field, with one plan to release mosquitoes in 
Brazil. Effectiveness against DENV should serve as data to predict whether 
introducing mosquitos with Wolbachia would also be a method to control ZIKV 
transmission (81).  
Strategies to avoid sexual transmission  
 Although ZIKV is unlikely 
to become a sexually 
transmitted epidemic (Figure 
10) , it still represents a 
particular public health 
challenge regarding sexual relations because it can both be transmitted sexually, 
and can lead to congenital microcephaly in an unplanned pregnancy (82). 
Therefore, methods to reduce adverse public health effects include goals that are 
directed at both avoiding transmission, through methods such as male and 
female condoms, antiviral drugs, and abstinence; and preventing unwanted 
pregnancy which includes the overlapping goals of condom use and abstinence, 
Figure 10. Low risk of sexually transmitted Zika virus outbreak 
(82). 
	 59	
but also includes easy and inexpensive access to abortions. These goals are 
summarized by the September 2016 WHO recommendations to reduce ZIKV 
transmission: all adults and especially pregnant women should receive 
counseling about the risks of sexual transmission; men and women should 
receive counseling about safe sex practices and receive free condoms; sexually 
active men and women should receive counseling and be offered a range of 
contraceptives to prevent possible adverse pregnancy and fetal outcomes; 
women who have had unsafe sex should have access to emergency 
contraceptives, and pregnant women should practice safe sex or abstain from 
sexual activity for the duration of pregnancy (83). While theoretically practical 
advice, these guidelines are particularly difficult to follow in Brazil where very 
few adolescents receive counseling on safe sex, there is restricted access to 
abortions, and limited family planning services (84).  
Male condom use 
Current estimates of condom use in Brazil differ among national studies. 
There is some consensus: most studies agree that condom use increased when, in 
1994, Brazil began implementing condom distribution programs and including 
male condoms in the Brazilian National Health System to combat the HIV/AIDS 
epidemic, and many studies cite a subsequent decline in condom use, at least 
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among some groups. Given that condoms are the most commonly used method 
of contraception and sexually transmitted infection (STI) prevention, a better 
assessment of the current rates of condom use would be a strong first step to 
curtailing the ZIKV outbreak and the increased rate of congenital microcephaly 
(85).  
Despite unclear results about the rate of overall condom use, studies have 
consistently found that those who are single or in casual relationships are more 
likely to use condoms than those who are married or in a stable relationship. 
Although condom use among those with multiple partners is helpful in stopping 
the spread of ZIKV through sexual transmission, the decrease in consistent 
condom use among those in stable relationships is a cause for concern given that 
women in this population are more likely to wish to conceive, and thus risk 
having children with congenital microcephaly (85).  
One key question, given that those of lower SES are already at increased 
risk from vector transmission, is whether they are also more likely to be infected 
with ZIKV via sexual transmission. Studies have found mixed results about 
whether lower SES is associated with decreased condom use, making this a 
crucial area for further research. However, there is a consistent link between 
higher education in women and increased condom use; given that SES and 
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education are correlated in Brazil, this strengthens the results of studies that 
found that lower SES is associated with decreased condom use. Regardless, given 
the increased susceptibility of this group to vector-borne transmission, there 
should be targeted interventions in this population to increase condom use in 
light of the ZIKV outbreak (85,87).    
Different interventions have been used to increase condom use, with 
mixed conclusions. One literature review found that overall, when using either 
group education or conversations with peers, the success has been inconsistent. 
However, using a combination of interventions was far more effective than 
focusing on a single practice, especially when female support groups were 
included since, they enable the women to feel confident bringing condom use 
into the relationship (85). A different study found that behavioral intervention in 
adolescents through education about safe sex practices significantly increased 
condom use, suggesting that this age group should be targeted (87).  
Female condom use 
Another option to decrease ZIKV transmission and the incidence of 
congenital microcephaly is through encouraging the use of female condoms 
(FCs). Although less commonly used than male condoms, studies have 
adequately demonstrated that the contraceptive failure rate of FCs, when used 
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consistently and correctly, is close to the lowest failure rate of male condoms. A 
study in Brazil also examined their efficacy in preventing STIs and concluded 
that, given the low number of viral copies of ZIKV, FCs are an acceptable method 
of to prevent ZIKV transmission even though there is slightly more semen 
exposure than with male condoms (88). This study also examined the effect of 
education about condom use on semen exposure. Although education on FC use 
did not lower semen exposure, participants reported fewer mechanical problems, 
which might lead to a more positive experience and thus encourage use. Given 
that up to a third of the population is illiterate in some parts of Brazil, an 
educational intervention could also benefit those unable to read instructions (89). 
FCs have additional advantages besides possibly contributing to the reduction in 
congenital microcephaly: FCs have been show to increase female empowerment, 
allow women to negotiate protection with their partners, promote healthy 
behavior, and increase sexual confidence and autonomy (90). These indirect 
benefits could be particularly important in the context of the ZIKV outbreak, 
which might lead some women to wish to delay pregnancy.ii 
Abortion  
 Abortion in Brazil is illegal except in the cases of rape, anencephaly, or 
danger to the mother’s life. This has not changed with the ZIKV epidemic, and in 
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fact conservatives in Brazil are working to increase the penalty for abortion of a 
baby with microcephaly (91). However, crackdowns on abortions are forcing 
women to seek procedures that are almost always unsafe, either performed by 
someone without proper training or in a setting without the minimum medical 
standards, and that lead to complications often resulting in hospitalization. 
WHO estimates that 20-30% of unsafe abortions result in reproductive tract 
infections, 20-40% result in upper genital tract infection and infertility, 2% of 
women become infertile, and 5% develop chronic infections (92,93).  
Before the ZIKV outbreak, estimates in Brazil for the number of women 
admitted every year to the hospital for abortion complications was around 
250,000, a number that has remained roughly the same since 1995, although up to 
14% of women in Latin America who face complications after an unsafe 
pregnancy do not seek care, so this number is likely higher (92,94).  In the current 
setting of the ZIKV outbreak the number of women seeking abortions is believed 
to have increased, although data is scare. One source, a charity that mails 
abortion pills to women in Brazil, found that requests have doubled from 
November 2015 to June 2016 (95). Given the risk to maternal health, 
decriminalizing of abortion in Brazil, at least in instances with proven 
microcephaly, is essential to reducing the negative impact of ZIKV.  
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Blood transfusions 
 Another concern for managing the ZIKV outbreak is transmission through 
the blood supply. Because the majority of patients are asymptomatic, relying on 
clinical manifestations to screen donors is not recommended. In February, 2016 
the FDA recommended that in areas without endemic ZIKV, any travelers 
returning from an area with endemic ZIKV wishing to donate blood be deferred 
for four weeks. In areas with endemic ZIKV, donors with sexual contact with 
males or with a history or symptoms of ZIKV are to be deferred. As of August 
2016, investigational nucleic acid testing (NAT) was to be phased in across the 
U.S. ZIKV tested blood should be prioritized to pregnant women, for 
intrauterine fetal transfusions, and for patients in the neonatal intensive care unit 
(96).   
CONCLUSION 
 Scientists have been aware of ZIKV for over half of a century, but the virus 
was never considered a serious threat to public health. This changed with the 
outbreak in Brazil and with the plethora of evidence linking ZIKV to 
microcephaly and GBS. Further research will help elucidate this connection and 
demonstrate whether microcephaly had not been reported before in conjuncture 
with ZIKV due to differences in the population affected in Africa versus Brazil, 
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the system of monitoring, or a change in the neurovirulence of the virus. 
Regardless, ZIKV serves as a reminder that the newest threat to public health can 
come from a source previously viewed as benign; hopefully a better 
understanding of what caused this change with ZIKV will allow for other threats 
to be predicted.  
 The best option of minimizing the burden of ZIKV is a vaccine. Although 
there are several promising candidates, ZIKV remains a challenging disease for a 
vaccination campaign due to safety concerns about delivering a vaccine to 
pregnant women and the possibility of antibody cross-reactivity in people who 
have previously been exposed to flaviviruses, either through infection or 
vaccination. Additionally, it is unclear what the best endpoint would be to test 
vaccine success, especially given the short period of viremia and the cross-
reactivity with serological testing.  
 In the interim, the most effective way to lower the incidence of 
microcephaly is through reducing ZIKV transmission via vector control. 
Although Brazil has long employed strategies to target the mosquito population, 
improved surveillance is a critical first step towards establishing a baseline so 
that the effectiveness of different strategies can be more easily quantified, and so 
that strategies can be implemented in the areas with the greatest need. In 
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addition to the traditional approaches of removing water containers and 
improving waste collection, the novel approaches of genetic modification or 
using Wolbachia are promising, and will hopefully inspire a movement away 
from reliance on insecticides.  
 The most recent ZIKV outbreak in Brazil also highlights women’s rights 
issues in Brazil. There is a need for more frequent and comprehensive sexual 
education, especially for adolescents, and the right to safe abortions must be 
guaranteed. Taking these measures will hopefully decrease ZIKV transmission, 
thereby reducing the incidence of infants born with microcephaly. 
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